BioAtla, Inc. (BCAB)
NASDAQ: BCAB · Real-Time Price · USD
0.4567
-0.0176 (-3.71%)
Jun 5, 2025, 4:00 PM - Market closed

Company Description

BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer.

The company’s lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and squamous cell carcinoma of head and neck.

It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for treating melanoma, renal cell carcinoma, colorectal cancer, and NSCLC; BA3182, a bispecific candidate to treat adenocarcinomas; BA3361, a CAB-Nectin-4-ADC for treating tumors; BA3142, a dual-CAB T-cell engager targeting B7-H3, a protein expressed on various solid tumors; and preclinical candidate for CAB-Nectin 4 x CAB-CD3.

The company was founded in 2007 and is headquartered in San Diego, California.

BioAtla, Inc.
BioAtla logo
Country United States
Founded 2007
IPO Date Dec 16, 2020
Industry Biotechnology
Sector Healthcare
Employees 61
CEO Jay Short

Contact Details

Address:
11085 Torreyana Road
San Diego, California 92121
United States
Phone 858 558 0708
Website bioatla.com

Stock Details

Ticker Symbol BCAB
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
IPO Price $18.00
CIK Code 0001826892
CUSIP Number 09077B104
ISIN Number US09077B1044
Employer ID 85-1922320
SIC Code 2836

Key Executives

Name Position
Dr. Jay M. Short Ph.D. Co-Founder, Chief Executive Officer and Chairman
Richard A. Waldron Senior Vice President and Chief Financial Officer
Dr. Eric L. Sievers M.D. Chief Medical Officer
Christian J. Vasquez CPA Chief Accounting Officer, Controller and Corporate Secretary
Susie Melody Senior Vice President of Human Resources
Dr. Cathy Chang Ph.D. Senior Vice President of Research and Development
Dr. Gerhard Frey Ph.D. Senior Vice President of Technology Development
Monica Sullivan Senior Vice President of Intellectual Property and Contracts
Sheri Lydick Chief Commercial Officer
Lisa M. Pelton Accounting Manager

Latest SEC Filings

Date Type Title
May 20, 2025 SCHEDULE 13G/A Filing
May 16, 2025 8-K Current Report
May 16, 2025 424B3 Prospectus
May 14, 2025 EFFECT Notice of Effectiveness
May 6, 2025 S-3 Registration statement under Securities Act of 1933
May 6, 2025 10-Q Quarterly Report
May 6, 2025 8-K Current Report
Apr 25, 2025 SCHEDULE 13G/A Filing
Apr 24, 2025 ARS Filing
Apr 24, 2025 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material